Molecular biology of von Willebrand disease

被引:0
|
作者
Melo-Nava, Brenda [1 ]
Penaloza, Rosenda [1 ]
机构
[1] IMSS, Ctr Med Nacl Siglo 21, Hosp Pediat, Unidad Invest Med Genet Humana, Mexico City 06700, DF, Mexico
来源
REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2007年 / 59卷 / 05期
关键词
von Willebrand factor; von Willebrand disease; bleeding; coagulation;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Von Willebrand Factor (VWF) is a large multimeric glycoprotein expressed in the megakaryocytes and endothelial cells of all vertebrates. It participates fundamentally in the primary and secondary hemostasis because it induces the adhesion of platelets to vascular subendothelium and promotes aggregation of platelets when blood vessels and capillaries are damaged. In addition, VWF links to factor VIII which avoids its proteolysis. The deficiency or the inadequate synthesis of the VWF causes von Willebrand disease (VWD), which is the most common hereditary bleeding disorder in humans principally from mucous and cutaneous sites. VWD is difficult to detect with accuracy due to interrelation among VWF with different components of hemostasis, although it is performed by different tests of haemostatic system, and the basic mechanisms in VWD are herein emphasized. The diagnosis of VWD is difficult due to the heterogeneous manifestation of the disease, which also complicates its classification. This article focuses on the molecular aspects of the disease and discusses their possible clinical implications.
引用
收藏
页码:401 / 408
页数:8
相关论文
共 50 条
  • [21] Von Willebrand disease
    Wilde, Jonathan T.
    CLINICAL MEDICINE, 2007, 7 (06) : 629 - 632
  • [22] Von Willebrand Factor and von Willebrand disease: new approaches to diagnosis
    Ines Woods, Adriana
    Noemi Blanco, Alicia
    Catalina Kempfer, Ana
    Paiva, Juvenal
    Ines Bermejo, Emilse
    Sanchez Luceros, Analia
    Angela Lazzari, Maria
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2016, 50 (02): : 273 - 289
  • [23] Advances in the diagnosis and management of von Willebrand disease
    Franchini, Massimo
    HEMATOLOGY, 2006, 11 (04) : 219 - 225
  • [24] Vonicog alfa for the treatment of von Willebrand disease
    Castaman, Giancarlo
    Linari, Silvia
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (05): : 549 - 554
  • [25] von Willebrand disease and von Willebrand factor
    Sadler, Brooke
    Castaman, Giancarlo
    O'Donnell, James S.
    HAEMOPHILIA, 2022, 28 : 11 - 17
  • [26] Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease
    Rydz, N.
    Grabell, J.
    Lillicrap, D.
    James, P. D.
    HAEMOPHILIA, 2015, 21 (05) : 636 - 641
  • [27] Prophylaxis in von Willebrand disease
    Massimo Franchini
    Giovanni Targher
    Giuseppe Lippi
    Annals of Hematology, 2007, 86 : 699 - 704
  • [28] Prophylaxis in von Willebrand disease
    Franchini, Massimo
    Targher, Giovanni
    Lippi, Giuseppe
    ANNALS OF HEMATOLOGY, 2007, 86 (10) : 699 - 704
  • [29] Diagnosis of von Willebrand disease
    Ingerslev, J
    Gürsel, T
    HAEMOPHILIA, 1999, 5 : 50 - 56
  • [30] Von Willebrand Disease: An Overview
    Bharati, K. Pavani
    Prashanth, U. Ram
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 73 (01) : 7 - 16